Enhancement of Angiogenesis by the Implantation of Self Bone Marrow Cells in a Rat Ischemic Heart Model

Kobayashi, Toshirô; Hamano, Kimikazu; Li, Tao‐Sheng; Katoh, Takahiko; Kobayashi, Sei; Matsuzaki, Masunori; Esato, Kensuke

doi:10.1006/jsre.2000.5828

Cited by 164 publications

(108 citation statements)

References 21 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…4,5 Other groups have obtained similar results, 6,7 and the angiogenesis induced by local implantation of autologous BMC in rats has been shown to improve the loss of physical function related to ischemia. 8 We investigated the safety of this treatment in a canine heart model.…”

mentioning

confidence: 73%

Local Implantation of Autologous Bone Marrow Cells for Therapeutic Angiogenesis in Patients With Ischemic Heart Disease. Clinical Trial and Preliminary Results.

et al. 2001

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 73%

Local Implantation of Autologous Bone Marrow Cells for Therapeutic Angiogenesis in Patients With Ischemic Heart Disease. Clinical Trial and Preliminary Results.

et al. 2001

Self Cite

View full text Add to dashboard Cite

“…86 Others showed that transendocardial delivery of unfractionated autologous BM-MNCs induced collateral formation and rescued ventricular function in hibernating porcine myocardium. [87][88][89][90] Orlic et al reported that implantation of bone marrow-derived Lin Ϫ /c-kit ϩ cells, a subpopulation of BM-MNCs, into the infarct border enhanced new vessel formation. 91 In rats with limb ischemia, local intramuscular delivery of autologous BM-MNCs restored blood flow and exercise in association with enhanced neovascularization of the ischemic muscle.…”

Section: Cell Therapy For Myocardial and Peripheral Ischemic Disease mentioning

confidence: 99%

“…103 Interestingly, statins also reduce senescence and stimulate proliferation of PB-EPCs by regulating the activity of telomerase and cell cycle genes. 89,104 Thus the therapeutic potential of endothelial progenitor cells could potentially be enhanced by noninvasive pharmacological manipulation and used to accelerate re-endothelialization of injured vessels and inhibit neointimal hyperplasia after revascularization procedures.…”

Section: Endothelial Cell Therapy For Vascular Repair and Bioengineermentioning

confidence: 99%

Therapeutic Potential of Endothelial Progenitor Cells in Cardiovascular Diseases

et al. 2005

View full text Add to dashboard Cite

Abstract-Endothelial dysfunction and cell loss are prominent features in cardiovascular disease. Endothelial progenitor cells (EPCs) originating from the bone marrow play a significant role in neovascularization of ischemic tissues and in re-endothelialization of injured blood vessels. Several studies have shown the therapeutic potential of EPC transplantation in rescue of tissue ischemia and in repair of blood vessels and bioengineering of prosthetic grafts. Recent small-scale trials have provided preliminary evidence of feasibility, safety, and efficacy in patients with myocardial and critical limb ischemia. However, several studies have shown that age and cardiovascular disease risk factors reduce the availability of circulating EPCs (CEPCs) and impair their function to varying degrees. In addition, the relative scarcity of CEPCs limits the ability to expand these cells in sufficient numbers for some therapeutic applications. Priority must be given to the development of strategies to enhance the number and improve the function of CEPCs. Furthermore, alternative sources of EPC such as chord blood need to be explored. Strategies for improvement of cell adhesion, survival, and prevention of cell senescence are also essential to ensure therapeutic viability. Genetic engineering of EPCs may be a useful approach to developing these cells into efficient therapeutic tools. In the clinical arena there is pressing need to standardize the protocols for isolation, culture, and therapeutic application of EPC. Large-scale multi-center randomized trials are required to evaluate the long-term safety and efficacy of EPC therapy. Despite these hurdles, the outlook for EPC-based therapy for cardiovascular disease is promising. (Hypertension. 2005;46:7-18.)

show abstract

“…Over the last several years numerous investigators have reported integration of bone marrow cells into the vasculature after either bone marrow transplantation or systemic or local injection in humans, dogs, cats, rabbits, rats, and mice (for example, Asahara et al, 1997;Shi et al, 1998;Crosby et al, 2000;Ikpeazu et al, 2000;Kobayashi et al, 2000;Murohara et al, 2000). Integration occurs in a variety of vascular beds, but there appear to be differences in the rates of incorporation among them.…”

Section: Physiological Relevance Of Endothelial Cell Progenitorsmentioning

confidence: 99%

Hemangioblasts, angioblasts, and adult endothelial cell progenitors

Schatteman

Awad

2003

Anat. Rec.

View full text Add to dashboard Cite

After decades of speculation, proof of embryonic hemangioblasts finally emerged a few years ago. Surprisingly, at about the same time, evidence for adult hemangioblasts began to appear, and recent single-cell bone marrow transplants have confirmed their existence. Embryonic and adult hemangioblasts appear to share antigenic determinants, including CD34, ACC133, and VEGFR2, although their phenotype may be plastic. They also respond to similar factors, prominent among them vascular endothelial growth factor (VEGF). In the adult, hemangioblasts reside principally in the bone marrow, although they may subsequently leave that niche to reside in nonhematopoietic tissues. A number of studies indicate that these cells or their progeny may be a significant source of endothelial cells in adult pathologic and nonpathologic vascularization, and may participate in vascular repair. In addition to hemangioblasts, a more differentiated source of endothelial cell progenitors may be present in the blood, namely, monocytes or monocytic-like cells. The relative importance of the two cell types in vivo is not clear, though endothelial cells derived from the two sources may not be identical, and hemangioblasts seem to provide a stimulus for differentiation of the monocytes. Treatment with exogenous bone marrow-derived cells can promote neovascularization, accelerate restoration of blood flow to ischemic tissues, and improve cardiac function after infarct. Hence, there is great hope that either alone, in combination with angiogenic factors, or as gene therapy vectors, we can harness these cells to treat ischemic and vascular diseases in the relatively near future. Anat Rec Part A 276A: 13-21, 2004.

show abstract

Enhancement of Angiogenesis by the Implantation of Self Bone Marrow Cells in a Rat Ischemic Heart Model

Cited by 164 publications

References 21 publications

Local Implantation of Autologous Bone Marrow Cells for Therapeutic Angiogenesis in Patients With Ischemic Heart Disease. Clinical Trial and Preliminary Results.

Local Implantation of Autologous Bone Marrow Cells for Therapeutic Angiogenesis in Patients With Ischemic Heart Disease. Clinical Trial and Preliminary Results.

Therapeutic Potential of Endothelial Progenitor Cells in Cardiovascular Diseases

Hemangioblasts, angioblasts, and adult endothelial cell progenitors

Contact Info

Product

Resources

About